These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 31703842

  • 1. Emerging JWA-targeted Pt(IV) prodrugs conjugated with CX-4945 to overcome chemo-immune-resistance.
    Chen F, Pei S, Wang X, Zhu Q, Gou S.
    Biochem Biophys Res Commun; 2020 Jan 15; 521(3):753-761. PubMed ID: 31703842
    [Abstract] [Full Text] [Related]

  • 2. Disruption of SSBs repair to combat platinum resistance via the JWA-targeted Pt(IV) prodrug conjugated with a wogonin derivative.
    Wang X, Li L, Pei S, Zhu Q, Chen F.
    Pharmazie; 2020 Mar 20; 75(2):94-101. PubMed ID: 32213241
    [Abstract] [Full Text] [Related]

  • 3. A CK2-targeted Pt(IV) prodrug to disrupt DNA damage response.
    Chen F, Huang X, Wu M, Gou S, Hu W.
    Cancer Lett; 2017 Jan 28; 385():168-178. PubMed ID: 27793693
    [Abstract] [Full Text] [Related]

  • 4. Reversal of cisplatin resistance in human gastric cancer cells by a wogonin-conjugated Pt(IV) prodrug via attenuating Casein Kinase 2-mediated Nuclear Factor-κB pathways.
    Chen F, Qin X, Xu G, Gou S, Jin X.
    Biochem Pharmacol; 2017 Jul 01; 135():50-68. PubMed ID: 28288821
    [Abstract] [Full Text] [Related]

  • 5. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
    Chen F, Xu G, Tian W, Gou S.
    Biochem Pharmacol; 2021 Nov 01; 193():114785. PubMed ID: 34562469
    [Abstract] [Full Text] [Related]

  • 6. Pt(IV) prodrugs containing microtubule inhibitors displayed potent antitumor activity and ability to overcome cisplatin resistance.
    Li L, Huang X, Huang R, Gou S, Wang Z, Wang H.
    Eur J Med Chem; 2018 Aug 05; 156():666-679. PubMed ID: 30031977
    [Abstract] [Full Text] [Related]

  • 7. Unique Use of Alkylation for Chemo-Redox Activity by a Pt(IV) Prodrug.
    Pathak RK, Dhar S.
    Chemistry; 2016 Feb 24; 22(9):3029-36. PubMed ID: 26807548
    [Abstract] [Full Text] [Related]

  • 8. JWA reverses cisplatin resistance via the CK2-XRCC1 pathway in human gastric cancer cells.
    Xu W, Chen Q, Wang Q, Sun Y, Wang S, Li A, Xu S, Røe OD, Wang M, Zhang R, Yang L, Zhou J.
    Cell Death Dis; 2014 Dec 04; 5(12):e1551. PubMed ID: 25476899
    [Abstract] [Full Text] [Related]

  • 9. Pt(IV) Prodrug Photoactivation: A Promising Strategy for Cancer Therapy.
    Tang L, Luo Y, Luo W, Sun G, Jiang Y, Zhang Z, Yue X, Li S, Liang L, Liu W, Hu J.
    Curr Protein Pept Sci; 2024 Dec 04; 25(10):797-813. PubMed ID: 38919078
    [Abstract] [Full Text] [Related]

  • 10. Emerging platinum(iv) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment.
    Wang Z, Deng Z, Zhu G.
    Dalton Trans; 2019 Feb 19; 48(8):2536-2544. PubMed ID: 30633263
    [Abstract] [Full Text] [Related]

  • 11. Photosensitive Pt(IV)-azide prodrug-loaded nanoparticles exhibit controlled drug release and enhanced efficacy in vivo.
    Xiao H, Noble GT, Stefanick JF, Qi R, Kiziltepe T, Jing X, Bilgicer B.
    J Control Release; 2014 Jan 10; 173():11-7. PubMed ID: 24511610
    [Abstract] [Full Text] [Related]

  • 12. JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks.
    Wang S, Gong Z, Chen R, Liu Y, Li A, Li G, Zhou J.
    Nucleic Acids Res; 2009 Apr 10; 37(6):1936-50. PubMed ID: 19208635
    [Abstract] [Full Text] [Related]

  • 13. Novel NF-κB Inhibitor-Conjugated Pt(IV) Prodrug to Enable Cancer Therapy through ROS/ER Stress and Mitochondrial Dysfunction and Overcome Multidrug Resistance.
    Wang M, Li G, Jiang G, Cai J, Liu Z, Huang R, Huang X, Wang H.
    J Med Chem; 2024 Apr 25; 67(8):6218-6237. PubMed ID: 38573870
    [Abstract] [Full Text] [Related]

  • 14. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG, Pan ZY, Zhang DY, Cao Q, Ji LN, Mao ZW.
    ACS Appl Mater Interfaces; 2020 Sep 30; 12(39):43444-43455. PubMed ID: 32883070
    [Abstract] [Full Text] [Related]

  • 15. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
    Chen H, Wang X, Gou S.
    J Inorg Biochem; 2019 Apr 30; 193():133-142. PubMed ID: 30731264
    [Abstract] [Full Text] [Related]

  • 16. Platinum(IV) Prodrugs.
    Venkatesh V, Sadler PJ.
    Met Ions Life Sci; 2018 Feb 05; 18():. PubMed ID: 29394022
    [Abstract] [Full Text] [Related]

  • 17. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent PtIV Anticancer Prodrug.
    Ma L, Wang N, Ma R, Li C, Xu Z, Tse MK, Zhu G.
    Angew Chem Int Ed Engl; 2018 Jul 16; 57(29):9098-9102. PubMed ID: 29806087
    [Abstract] [Full Text] [Related]

  • 18. Photoactivatable platinum complexes.
    Bednarski PJ, Mackay FS, Sadler PJ.
    Anticancer Agents Med Chem; 2007 Jan 16; 7(1):75-93. PubMed ID: 17266506
    [Abstract] [Full Text] [Related]

  • 19. New NSAID-Pt(IV) prodrugs to suppress metastasis and invasion of tumor cells and enhance anti-tumor effect in vitro and in vivo.
    Song XQ, Ma ZY, Wu YG, Dai ML, Wang DB, Xu JY, Liu Y.
    Eur J Med Chem; 2019 Apr 01; 167():377-387. PubMed ID: 30784875
    [Abstract] [Full Text] [Related]

  • 20. Platinum(iv) anticancer prodrugs - hypotheses and facts.
    Gibson D.
    Dalton Trans; 2016 Aug 16; 45(33):12983-91. PubMed ID: 27214873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.